Funding Support and Author Disclosures The SUMMIT trial was funded by Eli Lilly and Company. Dr Borlaug has received grants R01 HL128526, R01 HL162828, and U01 HL160226 from the National Heart, Lung, and Blood Institute; grant W81XWH2210245 from the United States Department of Defense; and has received grants from the Schoen Foundation AstraZeneca, Axon, Corvia, Novo Nordisk, and Tenax Therapeutics; he has received consulting fees from Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations; and is named inventor (US Patent number 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Dr Zile has received research support from the Department of Veterans Affairs; and consulting fees from Abbott, Adona Medical, Aria CV, Avery Therapeutics Inc, Boehringer Ingelheim, Boston Scientific, Cardiovascular Research Foundation (CRF) Clinical Trials Center, CVRx, DIASTOL Therapeutics, LLC, EBR, Edwards, Lilly, GenKardia, Innoventric, KestraMedical, Medtronic, Merck, Morphic Therapeutics, Novartis, Pulnova, Salubris Biotherapeutics, Sonata, SRNALYTICS Inc, V-WAVE, and Vectorious. Dr Kramer has received consulting fees from Eli Lilly. Dr Litwin has been on the patient selection committee for Corvia and Axon; and has received consulting fees from Novo Nordisk and Lilly. Drs Hurt, Murakami, and Ou are employed by Eli Lilly and Company. Dr Packer has received consulting fees from 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Lilly, Imara, Medtronic, Moderna, Novartis, Pharmacocosmos, Reata, Regeneron, Roche, and Salamandra. Dr Ye has reported that he has no relationships relevant to the contents of this paper to disclose.
PubMed
GLP-1 Therapies